246results about How to "Good sustained release" patented technology

An intravaginal drug delivery device comprises a device body comprising a hydrophobic carrier material having at least one channel defining at least one opening to the exterior of said device body, said at least one channel being adapted to receive at least one drug-containing insert; at least one drug-containing insert positioned in said at least one channel, said drug-containing insert capable of releasing a pharmaceutically effective amount of at least one drug suitable for intravaginal administration and containing about 1% to about 70% of at least one water-soluble release enhancer, both the drug and the water-soluble release enhancer dispersed in an insert carrier material; wherein said hydrophobic carrier material and said insert carrier material may be the same or different; and wherein said at least one drug-containing insert is exposed on said exterior of said device body when said intravaginal drug delivery device is in use.

The invention is intended for a treatment of severe infections using an injectable drug-delivery system comprising nanoparticles of a biodegradable polymer with incorporated antibacterial drug.

An apatite-coated solid composition which contains a biodegradable polymer and an apatite-coated solid composition which contains a biodegradable polymer and a medicinal substance have properties of sustained release and of osteoconductive activity.

The present invention discloses slow-release cationic anti-mud polycarboxylic-type high performance water reducer and a preparation method thereof. The slow-release cationic anti-mud polycarboxylic-type high performance water reducer is successfully synthesized from an unsaturated carboxylic acid, a polyether macromonomer, a cationic unsaturated monomer, an unsaturated esters, a crosslinking agent, a chain transfer agent, an oxidizing agent and a reducing agent as raw materials at room temperature without heat source. By introduction of the long-chain-ester crosslinking agent and the cationic unsaturated monomer, the slow-release cationic anti-mud polycarboxylic-type high performance water reducer has good slow-release and anti-mud effects, is low in admixing volume, high in water-reducing rate, excellent in slump retention ability, and not sensitive to mud contained in sand and stones, and the process does not require an additional heat source, an be carried out at room temperature, and is low in investment, low in cost, and suitable for large scale promotion and application.

A method is described for separating, retrieving and concentrating platelets from whole blood relying on aggregation of the platelets followed by filtration. This method eliminates the need of a centrifuge for separating said cells from blood. To obtain cellular concentrates of platelets, blood is mixed with compatible agents that will aggregate cells while retaining contained growth factors. The resulting aggregates can then be separated from blood by filtration. If desired, the filter-captured aggregates are subject to a brief washing cycle where they are washed clean of residual aggregating agent, plasma, and red cells. Aggregates can then be partly or wholly deaggregated and the cells retrieved. The result is a suspension of cells and small aggregates with therapeutic levels of concentrated blood cells with included growth factors that are available for delivery to a wound site. A device that accomplishes the aforementioned process is also described.

This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably α-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.

The present invention relates to compositions comprising stem cells and partially committed progenitor cells and to methods of controlling cell proliferation and differentiation, which can be used for expansion of stem cells and their subsequent differentiation. The present invention provides expanded population of essentially undifferentiated stem cells, which are useful in clinical procedures involving stem cell therapy, and a population derived thereof of which at least part of the cells are differentiated. The cells can be used per se, as a part of a cell-bearing composition comprising cross-linked hyaluronic acid-laminin gels or as a part of a composite implant for tissue regeneration.

The present invention provides long-acting sustained-release formulations of drugs such as proteins or peptides, which are injectable, completely biodegradable and safe, as well as ensuring efficient encapsulation of the drugs such as proteins or peptides without inhibiting their biological activity. It is possible to achieve injectable sustained-release formulations that ensure efficient encapsulation and long-term sustained release of drugs such as proteins or peptides while retaining their biological activity, when a solution containing a drug and a polysaccharide derivative such as hyaluronic acid having a crosslinkable functional group(s) or a salt thereof is dehydrated in microparticulate form starting from a dilute state, where crosslinking proceeds slowly, to reach a concentration which facilitates crosslinking, to thereby cause crosslinking reaction during concentration, so that the drug is encapsulated into the crosslinked polysaccharide to give drug-carrying microparticles.

The present invention is slow released ClO2 air disinfectant, and belongs to the field of hygienic disease controlling and sterilizing technology. The slow released ClO2 air disinfectant consists of ClO2 solution in 1-3 weight portions, silicon gel as the carrier of ClO2 solution in 3 and activator in 0.005-0.1 weight portions. The slow released ClO2 air disinfectant has homogeneous and lasting release to maintain proper ClO2 concentration in the air and reach excellent air disinfecting effect. The used silicon gel may be recovered and reused after treatment.

The invention discloses a swelling-type hollow silk fibroin micro-needle drug delivery system and a preparation method thereof. According to the technical scheme of the preparation method, a swelling modified silk fibroin solution is casted in a PDMS mold to be vacuumized, dried and molded as a hollow needle-type housing. After that, a silk fibroin micro-needle array provided with cavities in the hollow needle-type housing is filled with powder-like or solution-like drugs, vacuumizing and drying are carried out to form a drug part. Finally, a layer of modified silk fibroin solution is cast, dried and molded as a cladded coating. The cladded coating is removed to obtain the swelling-type hollow silk fibroin micro-needle drug delivery system. The drugs are wrapped inside the cavities of the silk fibroin micro-needle arrays, so that the system is high in drug loading ratio and low in skin allergenicity and stimulation. The system facilitates the sustained release and the controlled release of micro-needle drugs. Meanwhile, according to the preparation method, since the swelling modified silk fibroin solution is cast, dried and molded in a mild processing condition, the system is low in processing cost and suitable for large-scale production. Drugs are directly wrapped in the cavities of the swelling hollow micro-needles, so that controlled-release drugs are swelled in the micro-needle base material. In this way, the biological activities of the controlled-release drugs are maintained, while the structure of the hollow silk fibroin micro-needle drug delivery system is greatly simplified. The system is better in practicality.

The invention provides a foam dressing containing a composite silver-zinc antibacterial material and a preparation method of the foam dressing. The foam dressing containing the composite silver-zinc antibacterial material comprises polyurethane foaming plastic and the composite silver-zinc antibacterial material, wherein the composite silver-zinc antibacterial material is adhered to the inside of the polyurethane foaming plastic, comprises the following raw materials in content: nano silver, nano zinc and a nano inorganic carrier; and the composite silver-zinc antibacterial material contains the following raw materials in percentage by mass: 10%-20% of silver and 20%-40% of zinc. The composite silver-zinc antibacterial material is dispersed into the foam dressing in a manner of foam molding or ultrasonic dipping together with foam. The foam dressing containing the composite silver-zinc antibacterial material is capable of effectively absorbing diffusate of the wound surface, and effectively inhibiting growth and breeding of staphylococcus aureus, pseudomonas aeruginosa and candida albicans.

Disclosed is a sustained-release lipid pre-concentrate, comprising: a) at least one liquid crystal former; b) at least one neutral phospholipid; c) at least one liquid crystal hardener; and d) at least one anionic anchoring agent, wherein the sustained-release pre-concentrate exists as a lipid liquid phase in the absence of aqueous fluid and forms into a liquid crystal upon exposure to aqueous fluid. The sustained-release lipid pre-concentrate is configured to enhance the sustained release of cationic pharmacologically active substance through ionic interaction between the anionic anchoring agent and the cationic pharmacologically active substance.

The invention belongs to the concrete additive synthesis field, and concretely discloses a polyethylene glycol methyl ether maleate used for synthesizing a hyper-dispersant, and a preparation method and an application thereof. The preparation method concretely comprises the following steps: adding maleic anhydride and polyethylene glycol monomethyl ether into a reactor, heating to 60DEG C, and carrying out melt mixing; adding a polymerization inhibitor and a catalyst, uniformly stirring, letting in nitrogen, reacting at 90DEG C for 2h to generate an intermediate polyethylene glycol monomethyl ether maleate; and heating to 140-180DEG C, and carrying out a constant temperature stirring reaction for 4-10h to obtain the polyethylene glycol methyl ether maleate. The polyethylene glycol methyl ether maleate prepared through the method can be used for synthesizing hyper-dispersants. The preparation method has the advantages of easy operation, no need of a water carrying agent, simple reaction technology, high esterification rate, few byproudcts, no need of post-tretmetn, realization of the implementation of the reactions under normal pressure, mild reaction conditions, less apparatus investment and low energy consumption.

The invention relates to a method for preparing W/O/W type compound emulsion embedding an chlorogenic acid, belonging to the field of compound emulsion preparation and comprising the following steps: mixing 1 part of aqueous chlorogenic acid solution by weight, 2 parts of oil phases by weight and 0.2-0.4 part of lipophilic emulsifier by weight to be stirred for 4-10 minutes under the speed of 6,000-15,000 turns/minute so as to obtain W/O type colostrums; and then mixing 2-3 parts of the W/O type colostrums and 2-3 parts of external water phrases to be stirred for 2-10 minutes under the speed of 1000-6000 turns/minute so as to obtain the W/O/W type compound emulsion. The method for preparing the W/O/W type compound emulsion can not only play roles of protection and storage on the chlorogenic acid, but also realize the uniform and effective release of the chlorogenic acid in human bodies, and also promotes the slow release, the controlled release and the target effect of absorption and sufficiently plays a role of the chlorogenic acid by embedding the hlorogenic acid with the W/O/W type compound emulsion.

The invention discloses a fluid bed tablet-coating machine, which is characterized by the following: possessing dry air inlet and tank of ventilating port; arranging air flow distribution plate and filter in the tank; arranging at least two big hole area on the same angular of even dispersing on the air flow dispersing plate; setting the perforated ratio of the big hole area at 65%; arranging guide barrel on the upper of the air flow dispersing plate; heading on each big hole area; possessing gap between the floor of the guide barrel and the air flow dispersing plate; arranging a dressing injector; corresponding to each guide barrel; projecting the dressing injector from the central hole of the big hole area of the air flow dispersing plate. This invention possesses high output, which can be fit for big scale industrial production.

The invention relates to the treatment of localized pain by providing sustained release of an agent suitable for treating pain, methods for preparing and administering the agent, and methods of formulating and administering the agent as a pharmaceutical preparation. The agent can be locally administered to reduce systemic concentrations of the agent.

The present invention relates to a method for preparing supercritical nanoparticles of vitamin K by a supercritical fluid process.

The basic concept of the preparation method is as follows. A nanoscaled vitamin K complex is prepared by dissolving vitamin K and a biodegradable polymer in a suitable amount of an organic solvent, spraying the solution into a reactor equilibrated with a supercritical carbon dioxide via a nozzle to obtain particles, introducing supercritical carbon dioxide several times to the particles, extracting the organic solvent out, and then removing carbon dioxide.